← FDA DRUG APPROVALS

FDA ANDA · ANDA214842

POSACONAZOLE

Sponsor: EUGIA PHARMA

APPLICATION
ANDA214842
TYPE
ANDA
ORIGINAL APPROVAL
2023-12-26
LATEST ACTION
2023-12-26
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

POSACONAZOLEPrescription
POSACONAZOLE 300MG/16.7ML (18MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2023-12-26UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →